EGFR-targeted Therapy for Gastric Cancer
Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.
Adenocarcinoma of the Stomach
DRUG: Anti-EGFR antibody in combination with weekly paclitaxel
Response rate, Response rate will be assessed using CT/MRI according to RECIST v1.1., Response rate will be assessed at 8 weeks.
Progression-free survival, Time from date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed., From date of enrollment until the date of first documented progression or the date of death from any cause, whichever came first, will be assessed up to 1 year.
Participants will receive each treatment if the gastric cancer tissue sample reveals either EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining